Understanding Perceived Access and Receipt of Gender-affirming Treatments Among Transgender Veterans
1 other identifier
observational
986
1 country
1
Brief Summary
Transgender Veterans (trans Vets) frequently experience gender dysphoria or distress related to discord between their gender identity and birth sex. Gender-affirming treatments (GATs) are medically necessary treatments to reduce gender dysphoria. However, not much is known about the barriers and facilitators that influence GAT access and receipt in VA and VA Community Care (CC), among trans Vets who desire GATs. The goals of this mixed-methods study are to determine which GATs trans Vets receive and in which setting, identify barriers and facilitators associated with desired GAT receipt in VA and CC, examine association of GAT receipt, specifically mental healthcare and hormone therapy, with mental health and suicide risk and understand trans Vet experiences related to receipt and desire for mental healthcare and hormone therapy in VA and CC.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2024
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 23, 2024
CompletedFirst Posted
Study publicly available on registry
September 26, 2024
CompletedStudy Start
First participant enrolled
October 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 18, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
January 18, 2025
CompletedResults Posted
Study results publicly available
January 28, 2026
CompletedJanuary 28, 2026
January 1, 2026
4 months
September 23, 2024
January 13, 2026
January 13, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Receipt of Gender Affirming Treatment
Through a national survey, the investigators will identify receipt of gender-affirming treatment in VA and VA Community Care among transgender and gender diverse Veterans.
About 3.5 months
Study Arms (1)
Transgender and Gender Diverse Veterans
Veterans with documentation of either a gender identity disorder diagnoses, self-identified gender identity as transgender and gender diverse or transgender-related health factor.
Eligibility Criteria
Transgender and gender diverse veterans as identified by documentation of gender identity disorder diagnoses, self-identified gender identity and transgender-related health factors.
You may qualify if:
- All veterans with documentation of gender identity disorder diagnoses
- Self-reported gender identity as transgender and relevant transgender-related health factor
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
VA Bedford HealthCare System, Bedford, MA
Bedford, Massachusetts, 01730-1114, United States
Related Publications (1)
Jasuja GK, Zocchi MS, Reisman JI, Brady JE, Livingston NA, Blosnich JR, Vimalananda VG, Singh RS, Goodman M, Silverberg MJ, Wormwood JB, Shipherd JC. Using Self-Identified Gender Identity Data to Advance Health Equity Among Transgender and Gender Diverse Veterans in the Veterans Health Administration. Med Care. 2025 Nov 1;63(11):833-841. doi: 10.1097/MLR.0000000000002195. Epub 2025 Sep 26.
PMID: 41001883RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Guneet Jasuja
- Organization
- VA Bedford Healthcare System
Study Officials
- PRINCIPAL INVESTIGATOR
Guneet K. Jasuja, PhD
VA Bedford HealthCare System, Bedford, MA
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- FED
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 23, 2024
First Posted
September 26, 2024
Study Start
October 1, 2024
Primary Completion
January 18, 2025
Study Completion
January 18, 2025
Last Updated
January 28, 2026
Results First Posted
January 28, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share